title: RBC autoantibodies in autoimmune lymphoproliferative syndrome.
abstract: BACKGROUND
  Patients with autoimmune lymphoproliferative syndrome (ALPS) have an autosomal dominant genetic defect that affects lymphocyte apoptosis and is associated with chronic nonmalignant lymphadenopathy, splenomegaly, and autoimmunity, particularly affecting RBCs, WBCs, and platelets.
  
  
  METHODS
  DATs were performed on 34 consecutive patients with ALPS and 37 of their clinically unaffected relatives. The effects of age, sex, race, and immunoglobulin levels on the incidence of autoantibodies and clinical hemolysis were assessed.
  
  
  RESULTS
  The DAT was positive in 21 (62%) of ALPS patients but in only 1 (3%) of their relatives (p = 0.001). The DAT reacted because of IgG alone in 43 percent, complement alone in 5 percent, and IgG plus complement in 19 percent; 33 percent of the patients' cells had a positive reaction with polyspecific reagent only. All 10 ALPS patients with a history of hemolytic anemia had a positive DAT. Sixty percent of them had only IgG on their cells, 30 percent had IgG and complement, and 10 percent reacted only with polyspecific reagent. Of the 11 patients with a positive DAT and no history of hemolytic anemia, IgG alone was present in 27 percent, complement alone in 9%, and IgG plus complement in 9 percent; 55 percent had positive DATs only with polyspecific reagent. Among ALPS patients, those with a positive DAT had greater quantities of cells with increased alpha and ss T-cell receptors that phenotyped as CD4-CD8- and higher IgG levels.
  
  
  CONCLUSIONS
  The DAT results in ALPS patients are most similar to those found in warm autoimmune hemolytic anemia. The DAT is useful to distinguish affected and unaffected persons within an ALPS family.
authors.affiliation: Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institute of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, Bethesda, Maryland 20892-1184, USA. dstroncek@dtm.cc.nih.gov
authors.forename: D F
authors.initials: DF
authors.lastname: Stroncek
authors.forename: L B
authors.initials: LB
authors.lastname: Carter
authors.forename: J L
authors.initials: JL
authors.lastname: Procter
authors.forename: J K
authors.initials: JK
authors.lastname: Dale
authors.forename: S E
authors.initials: SE
authors.lastname: Straus
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000372:Agglutination Tests; D017209:Apoptosis; D001323:Autoantibodies / Q000032:analysis*; D001327:Autoimmune Diseases / Q000145:classification / Q000150:complications / Q000235:genetics / Q000276:immunology*; D002648:Child; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000145:classification / Q000150:complications / Q000235:genetics / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009503:Neutropenia / Q000209:etiology; D012016:Reference Values; D013921:Thrombocytopenia / Q000209:etiology; D013997:Time Factors
chemical_list: D001323:Autoantibodies